Clinical and economic burden of antimicrobial resistance

References

• Perencevich EN, Stone PW, Wright SB, Carmeli Y, Fisman DN, Cosgrove SE. Raising standards while watching the bottom line: making a business case for infection control. Infect. Control Hosp. Epidemiol.28(10), 1121–1133 (2007).
   PubMedGoogle Scholar
• Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes (3rd Edition). Oxford University Press, USA (2005).
   Google Scholar
• Gold MR, Siegel JE, Russell LB, Weistein MC. Cost–Effectiveness in Health and Medicine. Oxford University Press, USA (1996).
   Google Scholar
• US Congress OoTA. Impacts of antibiotic-resistant bacteria, OTA-H-629 (1995).
   Google Scholar
• Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob. Agents Chemother.34(6), 1227–1231 (1990).
   PubMed Web of Science ®Google Scholar
• Gentry CA, Rodvold KA, Novak RM, Hershow RC, Naderer OJ. Retrospective evaluation of therapies for Staphylococcus aureus endocarditis. Pharmacotherapy17(5), 990–997 (1997).
   PubMed Web of Science ®Google Scholar
• Fowler VG, Jr., Kong LK, Corey GR et al. Recurrent Staphylococcus aureus bacteremia: pulsed-field gel electrophoresis findings in 29 patients. J. Infect. Dis.179(5), 1157–1161 (1999).
   PubMed Web of Science ®Google Scholar
• Levin AS, Barone AA, Penco J et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin. Infect. Dis.28(5), 1008–1011 (1999).
   PubMed Web of Science ®Google Scholar
• Rodman DP, McKnight JT, Rogers T, Robbins M. The appropriateness of initial vancomycin dosing. J. Fam. Pract.38(5), 473–477 (1994).
   PubMed Web of Science ®Google Scholar
• Niederman MS. Use of broad-spectrum antimicrobials for the treatment of pneumonia in seriously ill patients: maximizing clinical outcomes and minimizing selection of resistant organisms. Clin. Infect. Dis.42(Suppl. 2), S72–S81 (2006).
   PubMed Web of Science ®Google Scholar
• Lodise TP, McKinnon PS, Swiderski L, Rybak MJ. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin. Infect. Dis.36(11), 1418–1423 (2003).
   PubMed Web of Science ®Google Scholar
• Lodise TP, McKinnon PS, Tam VH, Rybak MJ. Clinical outcomes for patients with bacteremia caused by vancomycin-resistant enterococcus in a level 1 trauma center. Clin. Infect. Dis.34(7), 922–929 (2002).
   PubMed Web of Science ®Google Scholar
• Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin. Infect. Dis.32(8), 1162–1171 (2001).
   PubMed Web of Science ®Google Scholar
• Paterson DL, Ko WC, Von GA et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum β-lactamases. Clin. Infect. Dis.39(1), 31–37 (2004).
   PubMed Web of Science ®Google Scholar
• Hyle EP, Lipworth AD, Zaoutis TE, Nachamkin I, Bilker WB, Lautenbach E. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae: variability by site of infection. Arch. Intern. Med.165(12), 1375–1380 (2005).
   PubMedGoogle Scholar
• Lautenbach E, Metlay JP, Bilker WB, Edelstein PH, Fishman NO. Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: the role of inadequate empirical antimicrobial therapy. Clin. Infect. Dis.41(7), 923–929 (2005).
   PubMed Web of Science ®Google Scholar
• Kang CI, Kim SH, Kim HB et al.Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin. Infect. Dis.37(6), 745–751 (2003).
   PubMed Web of Science ®Google Scholar
• Kang CI, Kim SH, Park WB et al. Bloodstream infections caused by antibiotic-resistant Gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob. Agents Chemother.49(2), 760–766 (2005).
   PubMed Web of Science ®Google Scholar
• Carmeli Y, Troillet N, Karchmer AW, Samore MH. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch.Intern. Med.159(10), 1127–1132 (1999).
   PubMed Web of Science ®Google Scholar
• Cosgrove SE, Kaye KS, Eliopoulous GM, Carmeli Y. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch. Intern. Med.162(2), 185–190 (2002).
   PubMed Web of Science ®Google Scholar
• Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin. Infect. Dis.42(11), 1578–1583 (2006).
   PubMed Web of Science ®Google Scholar
• Bishop E, Melvani S, Howden BP, Charles PG, Grayson ML. Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. Antimicrob. Agents Chemother.50(4), 1599–1602 (2006).
   PubMed Web of Science ®Google Scholar
• Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann. Intern. Med.115(9), 674–680 (1991).
   PubMed Web of Science ®Google Scholar
• Carmeli Y, Eliopoulos G, Mozaffari E, Samore M. Health and economic outcomes of vancomycin-resistant enterococci. Arch. Intern. Med.162(19), 2223–2228 (2002).
   PubMed Web of Science ®Google Scholar
• Harris A, Torres-Viera C, Venkataraman L, DeGirolami P, Samore M, Carmeli Y. Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa. Clin. Infect. Dis.28(5), 1128–1133 (1999).
   PubMed Web of Science ®Google Scholar
• Linden PK, Pasculle AW, Manez R et al. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin. Infect. Dis.22(4), 663–670 (1996).
   PubMed Web of Science ®Google Scholar
• Baba T, Takeuchi F, Kuroda M et al. Genome and virulence determinants of high virulence community-acquired MRSA. Lancet359(9320), 1819–1827 (2002).
   PubMed Web of Science ®Google Scholar
• Naimi TS, LeDell KH, Como-Sabetti K et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA290(22), 2976–2984 (2003).
   PubMed Web of Science ®Google Scholar
• Bjorkman J , Andersson DI. The cost of antibiotic resistance from a bacterial perspective. Drug Resist. Updat.3(4), 237–245 (2000).
   PubMed Web of Science ®Google Scholar
• Schulgen G, Kropec A, Kappstein I, Daschner F, Schumacher M. Estimation of extra hospital stay attributable to nosocomial infections: heterogeneity and timing of events. J. Clin. Epidemiol.53(4), 409–417 (2000).
   PubMedGoogle Scholar
• Cosgrove SE , Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin. Infect. Dis.36(11), 1433–1437 (2003).
   PubMed Web of Science ®Google Scholar
• Kaye KS, Engemann JJ, Mozaffari E, Carmeli Y. Reference group choice and antibiotic resistance outcomes. Emerg. Infect. Dis.10(6), 1125–1128 (2004).
   PubMedGoogle Scholar
• McCabe W, Jackson G. Gram-negative bacteremia. Arch. Intern. Med.110(847), 855 (1962).
   Google Scholar
• Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit. Care Med.13(10), 818–829 (1985).
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis.40(5), 373–383 (1987).
   PubMedGoogle Scholar
• Von KM, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J. Clin. Epidemiol.45(2), 197–203 (1992).
   PubMedGoogle Scholar
• Batista R, Kaye K, Yokoe DS. Admission-specific chronic disease scores as alternative predictors of surgical site infection for patients undergoing coronary artery bypass graft surgery. Infect. Control Hosp. Epidemiol.27(8), 802–808 (2006).
   PubMedGoogle Scholar
• McGregor JC, Kim PW, Perencevich EN et al. Utility of the Chronic Disease Score and Charlson Comorbidity Index as comorbidity measures for use in epidemiologic studies of antibiotic-resistant organisms. Am. J. Epidemiol.161(5), 483–493 (2005).
   PubMed Web of Science ®Google Scholar
• McGregor JC, Perencevich EN, Furuno JP et al. Comorbidity risk-adjustment measures were developed and validated for studies of antibiotic-resistant infections. J. Clin. Epidemiol.59(12), 1266–1273 (2006).
   PubMedGoogle Scholar
• Perencevich EN, Sands KE, Cosgrove SE, Guadagnoli E, Meara E, Platt R. Health and economic impact of surgical site infections diagnosed after hospital discharge. Emerg. Infect. Dis.9(2), 196–203 (2003).
   PubMed Web of Science ®Google Scholar
• Iezzoni LI. The risks of risk adjustment. JAMA278(19), 1600–1607 (1997).
   PubMed Web of Science ®Google Scholar
• Robins J. The control of confounding by intermediate variables. Stat. Med.8(6), 679–701 (1989).
   PubMed Web of Science ®Google Scholar
• Perencevich EN. Excess shock and mortality in Staphylococcus aureus related to methicillin resistance. Clin. Infect. Dis.31(5), 1311–1313 (2000).
   PubMedGoogle Scholar
• Hamilton KW, Bilker WB, Lautenbach E. Controlling for severity of illness in assessment of the association between antimicrobial-resistant infection and mortality: impact of calculation of Acute Physiology and Chronic Health Evaluation (APACHE) II scores at different time points. Infect. Control Hosp. Epidemiol.28(7), 832–836 (2007).
   PubMedGoogle Scholar
• Haley RW. Measuring the costs of nosocomial infections: methods for estimating economic burden on the hospital. Am. J. Med.91(3B), S32–S38 (1991).
   Google Scholar
• Finkler SA. The distinction between cost and charges. Ann. Intern. Med.96(1), 102–109 (1982).
   PubMed Web of Science ®Google Scholar
• Howard D, Cordell R, McGowan JE Jr, Packard RM, Scott RD, Solomon SL. Measuring the economic costs of antimicrobial resistance in hospital settings: summary of the Centers for Disease Control and Prevention – Emory Workshop. Clin. Infect. Dis.33(9), 1573–1578 (2001).
   PubMed Web of Science ®Google Scholar
• Ward WJ Jr, Spragens L, Smithson K. Building the business case for clinical quality. Healthc. Financ. Manage.60(12), 92–98 (2006).
   PubMedGoogle Scholar
• Conterno LO, Wey SB, Castelo A. Risk factors for mortality in Staphylococcus aureus bacteremia. Infect. Control Hosp. Epidemiol.19(1), 32–37 (1998).
   PubMed Web of Science ®Google Scholar
• Craven DE, Kollisch NR, Hsieh CR, Connolly MG Jr, McCabe WR. Vancomycin treatment of bacteremia caused by oxacillin-resistant Staphylococcus aureus: comparison with β-lactam antibiotic treatment of bacteremia caused by oxacillin-sensitive Staphylococcus aureus. J. Infect. Dis.147(1), 137–143 (1983).
   PubMedGoogle Scholar
• French GL, Cheng AF, Ling JM, Mo P, Donnan S. Hong Kong strains of methicillin-resistant and methicillin-sensitive Staphylococcus aureus have similar virulence. J. Hosp .Infect.15(2), 117–125 (1990).
   PubMed Web of Science ®Google Scholar
• Gonzalez C, Rubio M, Romero-Vivas J, Gonzalez M, Picazo JJ. Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin. Infect. Dis.29(5), 1171–1177 (1999).
   PubMed Web of Science ®Google Scholar
• Harbarth S, Rutschmann O, Sudre P, Pittet D. Impact of methicillin resistance on the outcome of patients with bacteremia caused by Staphylococcus aureus. Arch. Intern. Med.158(2), 182–189 (1998).
   PubMed Web of Science ®Google Scholar
• Hershow RC, Khayr WF, Smith NL. A comparison of clinical virulence of nosocomially acquired methicillin-resistant and methicillin-sensitive Staphylococcus aureus infections in a university hospital. Infect. Control Hosp. Epidemiol.13(10), 587–593 (1992).
   PubMedGoogle Scholar
• Lewis E, Saravolatz LD. Comparison of methicillin-resistant and methicillin-sensitive Staphylococcus aureus bacteremia. Am. J. Infect. Control13(3), 109–114 (1985).
   PubMedGoogle Scholar
• Marty L, Flahault A, Suarez B, Caillon J, Hill C, Andremont A. Resistance to methicillin and virulence of Staphylococcus aureus strains in bacteriemic cancer patients. Intensive Care Med.19(5), 285–289 (1993).
   PubMedGoogle Scholar
• McClelland RS, Fowler VG Jr, Sanders LL et al.Staphylococcus aureus bacteremia among elderly vs younger adult patients: comparison of clinical features and mortality. Arch. Intern. Med.159(11), 1244–1247 (1999).
   PubMedGoogle Scholar
• Mylotte JM, Aeschlimann JR, Rotella DL. Staphylococcus aureus bacteremia: factors predicting hospital mortality. Infect. Control Hosp. Epidemiol.17(3), 165–168 (1996).
   PubMed Web of Science ®Google Scholar
• Roghmann MC. Predicting methicillin resistance and the effect of inadequate empiric therapy on survival in patients with Staphylococcus aureus bacteremia. Arch. Intern. Med.160(7), 1001–1004 (2000).
   PubMedGoogle Scholar
• Romero-Vivas J, Rubio M, Fernandez C, Picazo JJ. Mortality associated with nosocomial bacteremia due to methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis.21(6), 1417–1423 (1995).
   PubMed Web of Science ®Google Scholar
• Selvey LA, Whitby M, Johnson B. Nosocomial methicillin-resistant Staphylococcus aureus bacteremia: is it any worse than nosocomial methicillin-sensitive Staphylococcus aureus bacteremia? Infect. Control Hosp. Epidemiol.21(10), 645–648 (2000).
   PubMed Web of Science ®Google Scholar
• Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin. Infect. Dis.36(1), 53–59 (2003).
   PubMed Web of Science ®Google Scholar
• Shurland S, Zhan M, Bradham DD, Roghmann MC. Comparison of mortality risk associated with bacteremia due to methicillin-resistant and methicillin-susceptible Staphylococcus aureus. Infect. Control Hosp. Epidemiol.28(3), 273–279 (2007).
   PubMed Web of Science ®Google Scholar
• Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect. Control Hosp. Epidemiol.26(2), 166–174 (2005).
   PubMed Web of Science ®Google Scholar
• Reed SD, Friedman JY, Engemann JJ et al. Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia. Infect.Control Hosp. Epidemiol.26(2), 175–183 (2005).
   PubMed Web of Science ®Google Scholar
• Capitano B, Leshem OA, Nightingale CH, Nicolau DP. Cost effect of managing methicillin-resistant Staphylococcus aureus in a long-term care facility. J. Am. Geriatr. Soc.51(1), 10–16 (2003).
   PubMed Web of Science ®Google Scholar
• Engemann JJ, Carmeli Y, Cosgrove SE et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin. Infect. Dis.36(5), 592–598 (2003).
   PubMed Web of Science ®Google Scholar
• Martinez-Aguilar G, valos-Mishaan A, Hulten K, Hammerman W, Mason EO Jr, Kaplan SL. Community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus musculoskeletal infections in children. Pediatr. Infect. Dis. J.23(8), 701–706 (2004).
   PubMed Web of Science ®Google Scholar
• Wang JL, Chen SY, Wang JT et al. Comparison of both clinical features and mortality risk associated with bacteremia due to community-acquired methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus. Clin. Infect. Dis.46(6), 799–806 (2008).
   PubMed Web of Science ®Google Scholar
• Miller LG, Quan C, Shay A et al. A prospective investigation of outcomes after hospital discharge for endemic, community-acquired methicillin-resistant and -susceptible Staphylococcus aureus skin infection. Clin. Infect. Dis.44(4), 483–492 (2007).
   PubMed Web of Science ®Google Scholar
• Edmond MB, Ober JF, Dawson JD, Weinbaum DL, Wenzel RP. Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin. Infect. Dis.23(6), 1234–1239 (1996).
   PubMed Web of Science ®Google Scholar
• Stosor V, Peterson LR, Postelnick M, Noskin GA. Enterococcus faecium bacteremia: does vancomycin resistance make a difference? Arch. Intern. Med.158(5), 522–527 (1998).
   PubMed Web of Science ®Google Scholar
• Bhavnani SM, Drake JA, Forrest A et al. A nationwide, multicenter, case–control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. Diagn. Microbiol. Infect. Dis.36(3), 145–158 (2000).
   PubMed Web of Science ®Google Scholar
• Yu VL, Chiou CC, Feldman C et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin. Infect. Dis.37(2), 230–237 (2003).
   PubMed Web of Science ®Google Scholar
• Fiore AE, Moroney JF, Farley MM et al. Clinical outcomes of meningitis caused by Streptococcus pneumoniae in the era of antibiotic resistance. Clin. Infect. Dis.30(1), 71–77 (2000).
   PubMed Web of Science ®Google Scholar
• Moroney JF, Fiore AE, Harrison LH et al. Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance. Clin. Infect. Dis.33(6), 797–805 (2001).
   PubMed Web of Science ®Google Scholar
• Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob. Agents Chemother.50(1), 43–48 (2006).
   PubMed Web of Science ®Google Scholar
• Gasink LB, Fishman NO, Nachamkin I, Bilker WB, Lautenbach E. Risk factors for and impact of infection or colonization with aztreonam-resistant Pseudomonas aeruginosa. Infect. Control Hosp. Epidemiol.28(10), 1175–1180 (2007).
   PubMedGoogle Scholar
• Gasink LB, Fishman NO, Weiner MG, Nachamkin I, Bilker WB, Lautenbach E. Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact. Am. J. Med.119(6), 526–525 (2006).
   PubMed Web of Science ®Google Scholar
• Lautenbach E, Weiner MG, Nachamkin I, Bilker WB, Sheridan A, Fishman NO. Imipenem resistance among Pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infect. Control Hosp. Epidemiol.27(9), 893–900 (2006).
   PubMed Web of Science ®Google Scholar
• Sunenshine RH, Wright MO, Maragakis LL et al. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg. Infect. Dis.13(1), 97–103 (2007).
   PubMed Web of Science ®Google Scholar
• Seifert H, Strate A, Pulverer G. Nosocomial bacteremia due to Acinetobacter baumannii. Clinical features, epidemiology, and predictors of mortality. Medicine (Baltimore)74(6), 340–349 (1995).
   PubMed Web of Science ®Google Scholar
• Kwon KT, Oh WS, Song JH et al. Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia. J. Antimicrob. Chemother.59(3), 525–530 (2007).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kopterides P, Siempos II. Attributable mortality of Acinetobacter baumannii infection among critically ill patients. Clin. Infect. Dis.43(3), 389–390 (2006).
   PubMedGoogle Scholar
• Lee NY, Lee HC, Ko NY et al. Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia. Infect. Control Hosp.Epidemiol.28(6), 713–719 (2007).
   PubMed Web of Science ®Google Scholar
• Abbo A, Carmeli Y, Navon-Venezia S, Siegman-Igra Y, Schwaber MJ. Impact of multi-drug-resistant Acinetobacter baumannii on clinical outcomes. Eur. J. Clin. Microbiol. Infect. Dis.26(11), 793–800 (2007).
   PubMed Web of Science ®Google Scholar
• Fournier PE , Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin. Infect. Dis.42(5), 692–699 (2006).
   PubMed Web of Science ®Google Scholar
• Albrecht MA, Griffith ME, Murray CK et al. Impact of Acinetobacter infection on the mortality of burn patients. J. Am. Coll.Surg.203(4), 546–550 (2006).
   PubMedGoogle Scholar
• Blot S, Vandewoude K, Colardyn F. Nosocomial bacteremia involving Acinetobacter baumannii in critically ill patients: a matched cohort study. Intensive Care Med.29(3), 471–475 (2003).
   PubMed Web of Science ®Google Scholar
• Chen HP, Chen TL, Lai CH et al. Predictors of mortality in Acinetobacter baumannii bacteremia. J. Microbiol.Immunol. Infect.38(2), 127–136 (2005).
   PubMedGoogle Scholar
• Choi JY, Park YS, Kim CO et al. Mortality risk factors of Acinetobacter baumannii bacteraemia. Intern. Med. J.35(10), 599–603 (2005).
   PubMedGoogle Scholar
• Falagas ME, Kasiakou SK, Rafailidis PI, Zouglakis G, Morfou P. Comparison of mortality of patients with Acinetobacter baumannii bacteraemia receiving appropriate and inappropriate empirical therapy. J. Antimicrob. Chemother.57(6), 1251–1254 (2006).
   PubMed Web of Science ®Google Scholar
• No authors listed. The cost of antibiotic resistance: effect of resistance among Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudmonas aeruginosa on length of hospital stay. Infect. Control Hosp. Epidemiol.23(2), 106–108 (2002).
   PubMed Web of Science ®Google Scholar
• Marchaim D, Navon-Venezia S, Schwaber MJ, Carmeli Y. Isolation of imipenem-resistant Enterobacter species: emergence of KPC-2 carbapenemase, molecular characterization, epidemiology, and outcomes. Antimicrob. Agents Chemother.52(4), 1413–1418 (2008).
   PubMed Web of Science ®Google Scholar
• Rice LB, Willey SH, Papanicolaou GA et al. Outbreak of ceftazidime resistance caused by extended-spectrum β-lactamases at a Massachusetts chronic-care facility. Antimicrob. Agents Chemother.34(11), 2193–2199 (1990).
   PubMed Web of Science ®Google Scholar
• Quale JM, Landman D, Bradford PA et al. Molecular epidemiology of a citywide outbreak of extended-spectrum β-lactamase-producing Klebsiella pneumoniae infection. Clin. Infect. Dis.35(7), 834–841 (2002).
   PubMedGoogle Scholar
• National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am. J. Infect. Control32(8), 470–485 (2004).
   PubMed Web of Science ®Google Scholar
• Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz D, Carmeli Y. Clinical and economic impact of bacteremia with extended-spectrum-β-lactamase-producing Enterobacteriaceae. Antimicrob. Agents Chemother.50(4), 1257–1262 (2006).
   PubMed Web of Science ®Google Scholar
• Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum β-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J. Antimicrob. Chemother.60(5), 913–920 (2007).
   PubMed Web of Science ®Google Scholar
• Zaoutis TE, Goyal M, Chu JH et al. Risk factors for and outcomes of bloodstream infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella species in children. Pediatrics115(4), 942–949 (2005).
   PubMed Web of Science ®Google Scholar
• Kim YK, Pai H, Lee HJ et al. Bloodstream infections by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob. Agents Chemother.46(5), 1481–1491 (2002).
   PubMed Web of Science ®Google Scholar
• Foglia EE, Fraser VJ, Elward AM. Effect of nosocomial infections due to antibiotic-resistant organisms on length of stay and mortality in the pediatric intensive care unit. Infect. Control Hosp. Epidemiol.28(3), 299–306 (2007).
   PubMed Web of Science ®Google Scholar